Henk-Jan Guchelaar (H J Guchelaar)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 46

Top Topics

Electronic Health Record

Epidermal Growth Factor Receptor

Top Venues

Clinical pharmacology and therapeutics

CPT: pharmacometrics & systems pharmacology

Clinical and translational science

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Fatima Zahra Marok, Jan-Georg Wojtyniak, Dominik Selzer, Robert Dallmann, Jesse Joachim Swen, Henk-Jan Guchelaar, Matthias Schwab, Thorsten Lehr
Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy. Clinical pharmacology and therapeutics (2024)
Anabel Beatriz Sanchez-Spitman, Stefan Böhringer, Vincent Olaf Dezentjé, André B P van Kuilenburg, Jesse Joachim Swen, Henk-Jan Guchelaar
A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients. Clinical pharmacology and therapeutics 116 (1) (2024)
Anna M Mc Laughlin, Thomas Helland, Fenja Klima, Stijn L W Koolen, Ron H N van Schaik, Ron H J Mathijssen, Patrick Neven, Jesse Joachim Swen, Henk-Jan Guchelaar, Florence Dalenc, Melanie White-Koning, Robin Michelet, Gerd Mikus, Werner Schroth, Thomas Mürdter, Hiltrud B Brauch, Matthias Schwab, Håvard Søiland, Gunnar Mellgren, Fabienne Thomas, Charlotte Kloft, Daniel Louis Hertz, null null
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Clinical pharmacology and therapeutics (2024)
Sylvia D Klomp, Anette Veringa, Jan Willem C Alffenaar, Mark G J de Boer, Lambert F R Span, Henk-Jan Guchelaar, Jesse Joachim Swen
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and translational science 17 (7) (2024)
Fatima Zahra Marok, Jan-Georg Wojtyniak, Dominik Selzer, Robert Dallmann, Jesse Joachim Swen, Henk-Jan Guchelaar, Matthias Schwab, Thorsten Lehr
Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy. Clinical pharmacology and therapeutics 115 (6) (2024)
Sylvia D Klomp, Anette Veringa, Jan Willem C Alffenaar, Mark G J de Boer, Lambert F R Span, Henk-Jan Guchelaar, Jesse Joachim Swen
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and translational science 17 (7) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology (2024)
Sylvia D Klomp, Anette Veringa, Jan Willem C Alffenaar, Mark G J de Boer, Lambert F R Span, Henk-Jan Guchelaar, Jesse Joachim Swen
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and translational science 17 (7) (2024)
Anabel Beatriz Sanchez-Spitman, Stefan Böhringer, Vincent Olaf Dezentjé, André B P van Kuilenburg, Jesse Joachim Swen, Henk-Jan Guchelaar
A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients. Clinical pharmacology and therapeutics (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Dirk Jan A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, Ron H J Mathijssen, J L Bakker, Vincent O Dezentjé, Nikki de Rouw, Nielka P van Erp, Egbert F Smit, Michel van den Heuvel, Thijs H Oude Munnink, Maartje van Kats, Sander Croes, Judith R Kroep, Juliette Zwaveling, Rob Ter Heine
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan. Targeted oncology (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anna M Mc Laughlin, Thomas Helland, Fenja Klima, Stijn L W Koolen, Ron H N van Schaik, Ron H J Mathijssen, Patrick Neven, Jesse Joachim Swen, Henk-Jan Guchelaar, Florence Dalenc, Melanie White-Koning, Robin Michelet, Gerd Mikus, Werner Schroth, Thomas Mürdter, Hiltrud B Brauch, Matthias Schwab, Håvard Søiland, Gunnar Mellgren, Fabienne Thomas, Charlotte Kloft, Daniel Louis Hertz, null null
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Clinical pharmacology and therapeutics 116 (3) (2024)
Fatima Zahra Marok, Jan-Georg Wojtyniak, Dominik Selzer, Robert Dallmann, Jesse Joachim Swen, Henk-Jan Guchelaar, Matthias Schwab, Thorsten Lehr
Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy. Clinical pharmacology and therapeutics (2024)
Sylvia D Klomp, Anette Veringa, Jan Willem C Alffenaar, Mark G J de Boer, Lambert F R Span, Henk-Jan Guchelaar, Jesse Joachim Swen
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and translational science 17 (7) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Sumudu Rangika Samarasinghe, Seung-Been Lee, Manuel Corpas, Segun Fatumo, Henk-Jan Guchelaar, Shivashankar H Nagaraj
Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented Population. Clinical pharmacology and therapeutics (2024)
Maryam Lyousoufi, Iris Lafeber, Dinemarie Kweekel, Brenda C M de Winter, Jesse Joachim Swen, Paul P H Le Brun, Erica C M Bijleveld-Olierook, Teun van Gelder, Henk-Jan Guchelaar, Dirk Jan A R Moes, Kirsten J M Schimmel
Development and bioequivalence of 3D-printed medication at the point-of-care: bridging the gap towards personalized medicine. Clinical pharmacology and therapeutics (2023)
Sofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, Emma C Hulshof, Ron H J Mathijssen, André B P van Kuilenburg, Henk-Jan Guchelaar, Jesse Joachim Swen
UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety. Pharmacogenomics (2023)
Jonathan E Knikman, Marta Lopez-Yurda, Didier Meulendijks, Maarten J Deenen, Jan H M Schellens, Jos H Beijnen, Annemieke Cats, Henk-Jan Guchelaar
A nomogram to predict severe toxicity in DPYD wild-type patients treated with capecitabine-based anticancer regimens. Clinical pharmacology and therapeutics (2023)
Maryam Lyousoufi, Iris Lafeber, Dinemarie Kweekel, Brenda C M de Winter, Jesse Joachim Swen, Paul P H Le Brun, Erica C M Bijleveld-Olierook, Teun van Gelder, Henk-Jan Guchelaar, Dirk Jan A R Moes, Kirsten J M Schimmel
Development and Bioequivalence of 3D-Printed Medication at the Point-of-Care: Bridging the Gap Toward Personalized Medicine. Clinical pharmacology and therapeutics (2023)
Henk-Jan Guchelaar, Jesse Swen
Reply to: Temporary Like Achilles: pre-emptive germline pharmacogenetic testing. Basic & clinical pharmacology & toxicology (2023)
Jonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, Didier M Meulendijks, Peter Nieboer, Helga J Droogendijk, Geert-Jan M Creemers, Caroline M P W Mandigers, Alexander L T Imholz, Ron H J Mathijssen, Johanneke E A Portielje, Liselot Valkenburg-van Iersel, Annelie Vulink, Marlene H W van der Poel, Arnold Baars, Jesse Joachim Swen, André B P van Kuilenburg, Jan H M Schellens, Jos H Beijnen, Henk-Jan Guchelaar, Annemieke Cats
Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Frank Eektimmerman, Jesse Joachim Swen, Alfons A den Broeder, Johanna M W Hazes, Fina S Kurreeman, Suzanne M M Verstappen, Nisha Nair, Andrzej Pawlik, Mike T Nurmohamed, Vita Dolžan, Stefan Böhringer, Cornelia F Allaart, Henk-Jan Guchelaar
Genome-wide association study of methotrexate-induced liver injury in rheumatoid arthritis patients. Clinical pharmacology and therapeutics (2023)
Frank Eektimmerman, Jesse Joachim Swen, Alfons A den Broeder, Johanna M W Hazes, Fina S Kurreeman, Suzanne M M Verstappen, Nisha Nair, Andrzej Pawlik, Mike T Nurmohamed, Vita Dolžan, Stefan Böhringer, Cornelia F Allaart, Henk-Jan Guchelaar
Genome-wide Association Study of Methotrexate-Induced Liver Injury in Rheumatoid Arthritis Patients. Clinical pharmacology and therapeutics (2023)
Frank Eektimmerman, Jesse Joachim Swen, Alfons A den Broeder, Johanna M W Hazes, Fina S Kurreeman, Suzanne M M Verstappen, Nisha Nair, Andrzej Pawlik, Mike T Nurmohamed, Vita Dolžan, Stefan Böhringer, Cornelia F Allaart, Henk-Jan Guchelaar
Genome-wide Association Study of Methotrexate-Induced Liver Injury in Rheumatoid Arthritis Patients. Clinical pharmacology and therapeutics 113 (4) (2023)
Frank Eektimmerman, Jesse Joachim Swen, Alfons A den Broeder, Johanna M W Hazes, Fina S Kurreeman, Suzanne M M Verstappen, Nisha Nair, Andrzej Pawlik, Mike T Nurmohamed, Vita Dolžan, Stefan Böhringer, Cornelia F Allaart, Henk-Jan Guchelaar
Genome-wide Association Study of Methotrexate-Induced Liver Injury in Rheumatoid Arthritis Patients. Clinical pharmacology and therapeutics 113 (4) (2023)
Henok D Habtemariam, Henk-Jan Guchelaar
The Potential Application of Extracellular Vesicles from Liquid Biopsies for Determination of Pharmacogene Expression. Pharmaceuticals (Basel, Switzerland) 15 (2) (2022)
Meta H M Diekstra, Jesse Joachim Swen, Loes F M van der Zanden, Sita H Vermeulen, Epie Boven, Ron H J Mathijssen, Koya Fukunaga, Taisei Mushiroda, Fumiya Hongo, Egbert Oosterwijk, Anne Cambon-Thomsen, Daniel Castellano, Achim Fritsch, Jesus Garcia Donas, Cristina Rodriguez-Antona, Rob Ruijtenbeek, Marius T Radu, Tim Eisen, Kerstin Junker, Max Roessler, Ulrich Jaehde, Tsuneharu Miki, Stefan Böhringer, Michiaki Kubo, Lambertus A L M Kiemeney, Henk-Jan Guchelaar
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Cancers 14 (12) (2022)
Sylvia A van Laar, Ellen H W Kapiteijn, Kim B Gombert-Handoko, Henk-Jan Guchelaar, Juliette Zwaveling
Application of Electronic Health Record Text Mining: Real-World Tolerability, Safety, and Efficacy of Adjuvant Melanoma Treatments. Cancers 14 (21) (2022)
Iris Lafeber, Elisabeth J Ruijgrok, Henk-Jan Guchelaar, Kirsten J M Schimmel
3D Printing of Pediatric Medication: The End of Bad Tasting Oral Liquids?-A Scoping Review. Pharmaceutics 14 (2) (2022)
Marije J Klumpers, Ward De Witte, Giovanna Gattuso, Elisabetta Schiavello, Monica Terenziani, Maura Massimino, Corrie E M Gidding, Sita H Vermeulen, Chantal M Driessen, Carla M Van Herpen, Esther Van Meerten, Henk-Jan Guchelaar, Marieke J H Coenen, D Maroeska W M Te Loo
Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury. Journal of personalized medicine 12 (6) (2022)
Mirjam de With, Jonathan E Knikman, Jan H M Schellens, André B P van Kuilenburg, Annemieke Cats, Henk-Jan Guchelaar, Ron H J Mathijssen, Jesse Joachim Swen, Didier Meulendijks
Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters". Clinical pharmacology and therapeutics (2022)
Ruth Van Daele, Yves Debaveye, Robin Vos, Pascal Van Bleyenbergh, Roger J M Brüggemann, Erwin Dreesen, Omar Elkayal, Henk-Jan Guchelaar, Pieter Vermeersch, Katrien Lagrou, Isabel Spriet
Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. Mycoses 64 (9) (2021)
Essra Youssef, Charlotte L Kirkdale, David John Wright, Henk-Jan Guchelaar, Tracey Thornley
Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK. British journal of clinical pharmacology 87 (7) (2021)
Maaike van der Lee, William G Allard, Rolf H A M Vossen, Renée F Baak-Pablo, Roberta Menafra, Birgit A L M Deiman, Maarten J Deenen, Patrick Neven, Inger Johansson, Stefano Gastaldello, Magnus Ingelman-Sundberg, Henk-Jan Guchelaar, Jesse Joachim Swen, Seyed Yahya Anvar
Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. Science translational medicine 13 (603) (2021)
Lisanne E N Manson, Wilbert B van den Hout, Henk-Jan Guchelaar
Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact Analysis. Pharmaceuticals (Basel, Switzerland) 15 (1) (2021)
Maaike van der Lee, Henk-Jan Guchelaar, Jesse Joachim Swen
Substrate specificity of CYP2D6 genetic variants. Pharmacogenomics 22 (16) (2021)
Maaike van der Lee, Marjolein Kriek, Henk-Jan Guchelaar, Jesse Joachim Swen
Technologies for Pharmacogenomics: A Review. Genes 11 (12) (2020)
Sylvia D Klomp, Martijn L Manson, Henk-Jan Guchelaar, Jesse Joachim Swen
Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. Journal of clinical medicine 9 (9) (2020)
Cathelijne H van der Wouden, Ellen Paasman, Martina Teichert, Matty R Crone, Henk-Jan Guchelaar, Jesse Joachim Swen
Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework. Journal of clinical medicine 9 (3) (2020)
M Y Eileen C van der Stoep, Juliette Zwaveling, Alice Bertaina, F Locatelli, Henk-Jan Guchelaar, Arjan C Lankester, Dirk Jan A R Moes
Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation. British journal of clinical pharmacology 85 (9) (2019)
Cathelijne H van der Wouden, Mandy H van Rhenen, Wafa O M Jama, Magnus Ingelman-Sundberg, Volker Martin Lauschke, Lidija Konta, Matthias Schwab, Jesse Joachim Swen, Henk-Jan Guchelaar
Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing. Clinical pharmacology and therapeutics 106 (4) (2019)
Cathelijne H van der Wouden, Paul C D Bank, Kübra Özokcu, Jesse Joachim Swen, Henk-Jan Guchelaar
Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact. Genes 10 (6) (2019)